Connecticut-based Braidwell disclosed a sale of 1,779,953 shares of Xenon Pharmaceuticals (NASDAQ:XENE) in its February 17, 2026, SEC filing, an estimated $74.76 million trade based on quarterly ...
Xenon Pharmaceuticals develops clinical-stage therapeutics targeting neurological disorders, including XEN496 and XEN1101 for epilepsy and related conditions. The company operates a research-driven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results